Guggenheim Lowers Eli Lilly and Company (NYSE:LLY) Price Target to $1,161.00

Eli Lilly and Company (NYSE:LLY) had its target price dropped by stock analysts at Guggenheim from $1,163.00 to $1,161.00 in a research note issued on Tuesday, Marketbeat reports. The brokerage currently has a “buy” rating on the stock. Guggenheim’s target price suggests a potential upside of 11.24% from the stock’s current price.

A number of other research analysts have also recently issued reports on LLY. Wall Street Zen upgraded shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 1st. HSBC reaffirmed a “hold” rating and set a $1,070.00 price objective on shares of Eli Lilly and Company in a research note on Wednesday, December 10th. Berenberg Bank boosted their target price on Eli Lilly and Company from $830.00 to $950.00 and gave the company a “hold” rating in a research note on Tuesday, December 2nd. Leerink Partners set a $1,234.00 price target on Eli Lilly and Company in a research report on Monday, January 5th. Finally, JPMorgan Chase & Co. lifted their price objective on Eli Lilly and Company from $1,050.00 to $1,150.00 and gave the company an “overweight” rating in a report on Tuesday, November 18th. Five equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $1,174.61.

Eli Lilly and Company Trading Up 0.5%

Shares of LLY stock traded up $5.30 during trading hours on Tuesday, reaching $1,043.70. The company had a trading volume of 362,532 shares, compared to its average volume of 2,847,809. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,133.95. The company has a 50 day moving average of $1,052.79 and a 200 day moving average of $873.30. The firm has a market cap of $986.69 billion, a price-to-earnings ratio of 50.68, a P/E/G ratio of 0.75 and a beta of 0.35.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating the consensus estimate of $6.42 by $0.60. The firm had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The company’s quarterly revenue was up 53.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, equities research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Institutional Trading of Eli Lilly and Company

A number of hedge funds and other institutional investors have recently modified their holdings of LLY. Lazard Freres Gestion S.A.S. lifted its position in Eli Lilly and Company by 114.3% during the second quarter. Lazard Freres Gestion S.A.S. now owns 77,295 shares of the company’s stock valued at $60,253,000 after buying an additional 41,222 shares during the period. Exencial Wealth Advisors LLC grew its holdings in Eli Lilly and Company by 189.6% in the third quarter. Exencial Wealth Advisors LLC now owns 17,408 shares of the company’s stock worth $13,283,000 after purchasing an additional 11,396 shares during the period. Rede Wealth LLC purchased a new stake in Eli Lilly and Company in the third quarter worth about $487,000. Precedent Wealth Partners LLC increased its stake in shares of Eli Lilly and Company by 15.3% during the second quarter. Precedent Wealth Partners LLC now owns 294 shares of the company’s stock valued at $229,000 after purchasing an additional 39 shares in the last quarter. Finally, Central Pacific Bank Trust Division lifted its holdings in shares of Eli Lilly and Company by 25.8% during the third quarter. Central Pacific Bank Trust Division now owns 8,990 shares of the company’s stock valued at $6,859,000 after purchasing an additional 1,843 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA grants Breakthrough Therapy designation to sofetabart mipitecan (LY4170156) for certain platinum‑resistant ovarian cancers — a regulatory acceleration that boosts the value of Lilly’s oncology pipeline and could shorten development timelines if confirmatory data pans out. Lilly’s sofetabart mipitecan receives U.S. FDA’s Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer
• Positive Sentiment: Phase results show Taltz + Zepbound combo delivered superior outcomes in a landmark psoriatic arthritis trial — positive efficacy data that could expand label use and drive incremental sales for Zepbound and Taltz. Eli Lilly’s Taltz and Zepbound combo delivers superior results in landmark psoriatic arthritis trial
• Positive Sentiment: Analyst commentary highlights Mounjaro and Zepbound as major growth drivers and notes an oral GLP‑1 near approval — reinforcing expectations for continued top‑line expansion and multiple revenue levers beyond injections. Which Pharma Stock Stands Taller Right Now: LLY or PFE?
• Positive Sentiment: Multiple bullish write‑ups (MarketBeat, The Motley Fool) position Lilly as a core way to play the GLP‑1 trend and broader late‑stage pipeline, supporting analyst earnings upgrades and investor demand. 3 Biotech Stocks That Look Like “Sure-Fire” Winners in 2026 (LLY) Prediction: 2026 Will Be the Year of Eli Lilly
• Neutral Sentiment: Industry ETF pieces note thematic exposure to GLP‑1 leaders (including Lilly) as pills emerge — useful for sector flows but neutral on company‑specific fundamentals. Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All (LLY)
• Neutral Sentiment: Rumors about a takeover of Abivax by Lilly were publicly dismissed by Abivax’s CEO — reduces takeover speculation but doesn’t affect Lilly’s operating outlook. Abivax CEO dismisses ‘noise’ around rumored Eli Lilly bid
• Negative Sentiment: Competitive pressure from Novo Nordisk’s newly launched oral Wegovy (strong early prescription uptake) is a near‑term threat to injectables and could weigh on Lilly until its oral GLP‑1 clears FDA review (decision expected in coming months). Eli Lilly vs. Novo Nordisk: Which Stock Has the Edge Right Now?

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.